DCP
NBIX icon

DSM Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

DSM Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-932,595
Closed -$127M – 43
2024
Q4 		$127M Sell
932,595
-11,559
-1% -$1.43M 1.97% 17
2024
Q3 		$109M Sell
944,154
-53,630
-5% -$7.35M 1.66% 18
2024
Q2 		$137M Sell
997,784
-138,218
-12% -$19M 1.99% 17
2024
Q1 		$157M Sell
1,136,002
-86,007
-7% -$11.7M 2.14% 16
2023
Q4 		$161M Sell
1,222,009
-2,008
-0.2% -$231K 2.46% 15
2023
Q3 		$138M Buy
1,224,017
+163,747
+15% +$17.2M 2.32% 14
2023
Q2 		$100M Sell
1,060,270
-199,261
-16% -$19.5M 1.62% 24
2023
Q1 		$127M Sell
1,259,531
-73,172
-5% -$7.61M 2.09% 23
2022
Q4 		$159M Buy
1,332,703
+10,501
+0.8% +$1.23M 2.65% 13
2022
Q3 		$140M Sell
1,322,202
-9,258
-0.7% -$939K 2.38% 15
2022
Q2 		$130M Sell
1,331,460
-19,871
-1% -$1.83M 2.18% 14
2022
Q1 		$127M Sell
1,351,331
-56,866
-4% -$4.82M 1.69% 23
2021
Q4 		$120M Sell
1,408,197
-104,913
-7% -$9.65M 1.26% 26
2021
Q3 		$145M Sell
1,513,110
-22,374
-1% -$2.11M 1.51% 21
2021
Q2 		$149M Buy
1,535,484
+186,977
+14% +$17.9M 1.44% 25
2021
Q1 		$131M Buy
1,348,507
+232,127
+21% +$24.3M 1.4% 23
2020
Q4 		$107M Buy
1,116,380
+279,614
+33% +$27M 1.15% 25
2020
Q3 		$80.5M Sell
836,766
-28,848
-3% -$3.34M 0.89% 24
2020
Q2 		$106M Buy
865,614
+5,561
+0.6% +$615K 1.26% 21
2020
Q1 		$74.4M Buy
860,053
+189,504
+28% +$18.5M 1.13% 24
2019
Q4 		$72.1M Buy
670,549
+19,336
+3% +$2.02M 0.95% 29
2019
Q3 		$58.7M Sell
651,213
-9,311
-1% -$870K 0.9% 28
2019
Q2 		$55.8M Sell
660,524
-35,658
-5% -$2.93M 0.81% 28
2019
Q1 		$61.3M Buy
+696,182
New +$58.2M 0.9% 29

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DSM Capital Partners's NBIX Position: Q1 2025 in Review

DSM Capital Partners sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 932,595 shares — an estimated $127M sold.

DSM Capital Partners first reported a position in NBIX in Q1 2019 and held it in 24 quarters. The position peaked at $161M in Q4 2023. 587 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • DSM Capital Partners reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • DSM Capital Partners sold 932,595 Neurocrine Biosciences shares in Q1 2025, an estimated $127M.
  • DSM Capital Partners first reported a position in Neurocrine Biosciences in Q1 2019 and held it in 24 quarters.
  • DSM Capital Partners's Neurocrine Biosciences position peaked at $161M in Q4 2023.
  • 587 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on DSM Capital Partners's 13F filing for Q1 2025, filed 13 May 2025.